NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise
CRISPR Therapeutics has delivered a steep share price decline of about 64.9% over the past 5 years, yet on broad valuation checks the stock now looks closer to fairly valued than like a clear bargain or clear bubble.
The roughly 64.9% slide over 5 years highlights how much long term shareholders have given up in returns, which naturally raises the bar for any new investment case.
Progress on CRISPR Therapeutics' allogeneic CAR-T programs, including the Phase 1 work on CTX112 aimed at off the...